Brilinta vs Lisinopril
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Brilinta | US Lisinopril | |
|---|---|---|
| Generic name | ticagrelor | lisinopril |
| Drug class | P2Y12 Platelet Inhibitor (Antiplatelet) | ACE Inhibitor |
| Treats | Acute coronary syndrome, heart attack prevention | High blood pressure, heart failure |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | AstraZeneca | Various (generic) |
| Year approved | 2011 | 1987 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $120M | $1M |
| Common side effects | Bleeding, Shortness of breath, Bruising, Headache | Dry cough, Dizziness, High potassium, Headache |
Lisinopril
Frequently asked questions
Is Brilinta or Lisinopril better?
Neither is universally "better." Brilinta (ticagrelor) and Lisinopril (lisinopril) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Brilinta and Lisinopril?
Brilinta is a P2Y12 Platelet Inhibitor (Antiplatelet) made by AstraZeneca, while Lisinopril is a ACE Inhibitor made by Various (generic). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Brilinta has the larger estimated TV advertising budget of the two.